@article{article_1487201, title={Can Apigenin Be an Effective Therapeutic Agent Against Experimental Renal Ischemia-Reperfusion Injury?}, journal={Pediatric Practice and Research}, volume={12}, pages={53–56}, year={2024}, DOI={10.21765/pprjournal.1487201}, author={Topdağı, Ömer and Güler, Mustafa Can and Eraslan, Ersen and Ekinci Akdemir, Fazile Nur and Tanyeli, Ayhan and Özbek Şebin, Saime and Şebin, Engin}, keywords={Apigenin, kidney, ischemia/reperfusion.}, abstract={Aim: This study aims to reveal the effects of two doses of apigenin (API) against renal ischemia-reperfusion injury (R I/R). Material and Methods: For this purpose, 5 and 10 mg/kg doses of API were preferred in our study, and the groups were designed as sham, R I/R, 5 mg/kg API, and 10 mg/kg API groups for the implementation of the experimental protocol. In the R I/R model, 1-hour ischemia and 24-hour reperfusion periods were preferred. Oxidative and inflammatory markers were measured biochemically in samples taken at the end of the experiment. Results: Biochemical results showed that oxidative and inflammatory markers increased significantly in the R I/R group, but antioxidant activities decreased significantly. In the 5 and 10 mg/kg API groups, R I/R damage was alleviated considerably, with these markers approaching the sham group values. Conclusion: As a result, the study’s results determined that two different doses of API were effective against R I/R-induced kidney damage.}, number={2}, publisher={Resul YILMAZ}